Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Advanced Breast Cancer
Related studies linked through entity extraction aliases.
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
- Status
- RECRUITING
- Phase
- PHASE2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Engage Psychosocial Intervention for Cancer Symptoms
- Status
- RECRUITING
- Phase
- NA
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
- Status
- RECRUITING
- Phase
- N/A
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
- Status
- COMPLETED
- Phase
- N/A
The COMPASSION Study
- Status
- RECRUITING
- Phase
- NA
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
- Status
- RECRUITING
- Phase
- N/A
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Status
- RECRUITING
- Phase
- PHASE2
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Status
- RECRUITING
- Phase
- PHASE3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3